Telotristat ethyl: a new option for the management of carcinoid syndrome

References

• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
   PubMed Web of Science ®Google Scholar
• Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, et al., editor. WHO classification of tumours of the digestive system. 4th. Lyon: International Agency for Research on cancer (IARC); 2010. p. 13. 2013.
   Google Scholar
• Scoazec JY, Couvelard A. [The new WHO classification of digestive neuroendocrine tumors]. Ann Pathol. 2011;31(2):88–92.
   PubMed Web of Science ®Google Scholar
• Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–138.
   PubMed Web of Science ®Google Scholar
• Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci. 1994;733:464–70.464–470.
   Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–1620.
   PubMed Web of Science ®Google Scholar
• Haverback BJ, Sjoerdsma A, Terry LL. Urinary excretion of the serotonin metabolite, 5-hydroxyindoleacetic acid, in various clinical conditions. N Engl J Med. 1956;255(6):270–272.
   PubMed Web of Science ®Google Scholar
• Strodel WE, Vinik AI, Jaffe BM, et al. Substance P in the localization of a carcinoid tumor. J Surg Oncol. 1984;27(2):106–111.
   PubMed Web of Science ®Google Scholar
• Gustafsen J, Boesby S, Nielsen F, et al. Bradykinin in carcinoid syndrome. Gut. 1987;28(11):1417–1419.
   PubMed Web of Science ®Google Scholar
• Roberts LJ, Bloomgarden ZT, Marney SR Jr., et al. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin. Gastroenterology. 1983;84(2):272–275.
   PubMed Web of Science ®Google Scholar
• Makridis C, Theodorsson E, Akerstrom G, et al. Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease. J Gastroenterol Hepatol. 1999;14(5):500–507.
   PubMed Web of Science ®Google Scholar
• Seymour N, Sawh SC. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review. Can J Anaesth. 2013;60(5):492–499.
   PubMed Web of Science ®Google Scholar
• Pearman TP, Beaumont JL, Cella D, et al. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016 Sep;24(9):3695–3703. DOI:10.1007/s00520-016-3189-z
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Cwikla J, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
   PubMed Web of Science ®Google Scholar
• Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217–223.
   PubMed Web of Science ®Google Scholar
• Wymenga AN, Eriksson B, Salmela P, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111.
   PubMed Web of Science ®Google Scholar
• Kvols LK. Treatment of the malignant carcinoid syndrome. N Engl J Med. 1986 Sep 11;315: 663–666. DOI:10.1056/NEJM198609113151102
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–771.
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23(4):412–415.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Ducreux M, Chayvialle J, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39(2):279–283.
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998;93(9):1468–1471.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? Cancer Treat Rev. 2016;44:26–41. Epub 2016 Jan 25. DOI:10.1016/j.ctrv.2016.01.005
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International lanreotide and interferon Alfa study group. J Clin Oncol. 2003;21(14):2689–2696.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol. 2014;20(39):14348–14358.
   PubMed Web of Science ®Google Scholar
• de Baere BT, Deschamps F, Tselikas L, et al. GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151–R166.
   PubMed Web of Science ®Google Scholar
• Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des DevelTher. 2015;9:5075–5086. eCollection;%2015.5075-5086. DOI:10.2147/DDDT.S84177
   PubMed Web of Science ®Google Scholar
• Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol. 1999;31Suppl:2S186–S189.
   Google Scholar
• Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125(1):26–34.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, et al. NETTER-1 phase III: progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. ASCO Annual Meeting 2016, abstract 194. J Clin Oncol. 2016; 34(suppl 4S; abstr 194). Available from: http://meetinglibrary.asco.org/content/160126-173.
   Google Scholar
• Seregni E, Maccauro M, Chiesa C, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41(2):223–230.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–523.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–275.
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–4771.
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Tangen CM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest oncology group study. Cancer. 1994;73(5):1505–1508.
   PubMed Web of Science ®Google Scholar
• Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study E1281. J Clin Oncol. 2005;23(22):4897–4904.
   PubMed Web of Science ®Google Scholar
• Childs A, Kirkwood A, Edeline J, et al. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocr Relat Cancer. 2016;23(7):563–570.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11(3):264–271.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71(8):2624–2630.
   PubMed Web of Science ®Google Scholar
• Roche A, Girish BV, De Baère T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13(1):136–140.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–2012.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977.
   PubMed Web of Science ®Google Scholar
• Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966–973.
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11(9):1127–1130.
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733–1742.
   PubMed Web of Science ®Google Scholar
• Liu EH, Solorzano CC, Katznelson L, et al. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21(5):534–545.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Bagante F, Wagner D, et al. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198(1):155–164.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of lanreotide depot/autogel efficacy and safety as carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016 Sep;22(9):1068–1080. DOI:10.4158/EP151172.OR
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Valle JW, Lombard-Bohas C, et al. Patient-reported outcomes with lanreotide autogel/depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48(5):552–558.
   PubMedGoogle Scholar
• Hauso O, Gustafsson BI, Loennechen JP, et al. Long-term serotonin effects in the rat are prevented by terguride. Regul Pept. 2007;143(1–3):39–46.
   PubMedGoogle Scholar
• Jackson LN, Chen LA, Larson SD, et al. Development and characterization of a novel in vivo model of carcinoid syndrome. Clin Cancer Res. 2009;15(8):2747–2755.
   PubMed Web of Science ®Google Scholar
• Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009;5(5):276–283.
   PubMed Web of Science ®Google Scholar
• Sung DJ, Noh HJ, Kim JG, et al. Serotonin contracts the rat mesenteric artery by inhibiting 4-aminopyridine-sensitive Kv channels via the 5-HT2A receptor and Src tyrosine kinase. Exp Mol Med. 2013;45:e67. DOI:10.1038/emm.2013.116.e67
   PubMed Web of Science ®Google Scholar
• Watts SW, Darios ES, Seitz BM, et al. 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol Res Perspect. 2015;3(1):e00103.
   Google Scholar
• Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151(1):107–112.
   PubMed Web of Science ®Google Scholar
• Faiss S, Rath U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999;60(5):469–476.
   PubMed Web of Science ®Google Scholar
• Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015;4(6):864–870.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930–936.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Weber J, Feldman M, et al. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res. 2013;6(3):81–85.
   PubMedGoogle Scholar
• Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21(6):1945–1955.
   PubMed Web of Science ®Google Scholar
• Fazio N, de Braud F, Delle FG, et al. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol. 2007;18(1):13–19.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Wang H, Terc JD, et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015;309(6):G455–G465.
   Google Scholar
• Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014;63(6):928–937.
   PubMed Web of Science ®Google Scholar
• Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med. 1967;277(21):1103–1108.
   PubMed Web of Science ®Google Scholar
• Cote F, Thevenot E, Fligny C, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA. 2003;100(23):13525–13530.
   PubMed Web of Science ®Google Scholar
• De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004;53(10):1520–1535.
   PubMed Web of Science ®Google Scholar
• NCBI. National Center for Biotechnology Information. PubChem Compound Database; CID= 25253377. 2016 [cited 2016 Jul.28]. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25253377
   Google Scholar
• Lapuerta P. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome. Clin Invest (Lond.). 2015;5(5):447–456.
   Google Scholar
• Erjavec I, Bordukalo-Niksic T, Brkljacic J, et al. Constitutively elevated blood serotonin is associated with bone loss and type 2 diabetes in rats. PLoS One. 2016;11(2):e0150102.
   PubMed Web of Science ®Google Scholar
• Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–714.
   PubMed Web of Science ®Google Scholar
• U.S.National Institutes of Health. ClinicaTrials.gov. 2016 [cited Sep 2016]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–1519.
   PubMed Web of Science ®Google Scholar
• Kulke M, Hörsch D, Caplin M. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. Journal of Clinical Oncology. 2016. doi:10.1200/JCO.2016.69.2780. [Epub ahead of print]
   Google Scholar
• Lexicon pr. 2015. http://www.lexpharma.com/news/press-releases/2408-telotristat.html
   Google Scholar
• Pavel M, Gross D, Benavent M, et al. Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double - blind Treatment Period of the TELECAST Phase 3 Clinical Trial. North American Neuroendocrine Tumor Society Annual Symposium 2016, Jackson, Wyoming. 2016 Sep 30–Oct 1. Available from: https://www.nanets.net/abstracts-2009-2016.
   Google Scholar
• Molina-Cerrillo J, Alonso-Gordoa T, Martinez-Saez O, et al. Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors. Oncologist. 2016;21(6):701–707.
   PubMed Web of Science ®Google Scholar
• Hörsch D, Kulke M, Caplin M, et al. Efficacy and Safety of Telotristat Etiprate in patients with carcinoid syndrome not adequatelly controlled by SSA tehrapy: analysis of the TELESTAR ongoing open-lable extension period. ENETS 13th Annual Conference, Barcelona, Spain. 2016 Mar 9–11. Available from: http://www.enets.org/13th_annual_conference_barcelona_2016.html.
   Google Scholar
• Musunuru S, Carpenter JE, Sippel RS, et al. A mouse model of carcinoid syndrome and heart disease. J Surg Res. 2005;126(1):102–105.
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Kulke MH, O’Dorisio T, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759–768.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yang Q, Sun W, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol ExpTher. 2008;325(1):47–55.
   PubMed Web of Science ®Google Scholar
• Lexicon pr. 2016 [cited 2016 Jul]. Available from: http://www.lexpharma.com/news/press-releases/2431-lexicon-announces-fda-priority-review-of-new-drug-application-for-telotristat-etiprate-for-the-treatment-of-carcinoid-syndrome.html
   Google Scholar